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Introduction 
 INTRODUCTION 
 Snake bite is a common emergency encountered in the tropical and sub 
tropical countries which abound with dense vegetations and vast tracts of 
agricultural land. India has always been known as the land of exotic snakes. 
Due to the prevailing climatic conditions and due to the fact that a major 
portion of the population is rural, with vast agricultural fields, snake bite is a 
major health problem. 
 In India, snake envenomation is one of the major causes of mortality 
and morbidity. In our country the estimated snake bite deaths is around 
15,000 per year. Though the village population is at a greater risk, the urban 
and suburban are not always spared. The latter can be attributed to unhygienic 
city dwelling, harboring rodents and the former is due to occupation, mainly 
farming. Envenomation of various poisonous species present a different 
clinical picture for an appropriate scientific management, this getting 
hampered by nonscientific natural treatment resulting in deaths and 
disabilities. 
 Though innumerable studies on snake bites are available, the purpose 
of this study is to highlight the epidemiology of snakebites with a stress on 
clinical presentation, complications and treatment.  
 
  
 
 
 
 
 
 
 
 
 
 
Aim of the Study 
 
AIM OF THE STUDY 
  
1. To analyse the epidemiology of snake bite. 
2. To study the clinical profile of snake bite victims. 
3. To authenticate the complications encountered. 
4. To assess the therapeutic options in envenomated individuals and 
outcome. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Review of Literature 
 REVIEW OF LITERATURE 
3.1 EPIDEMIOLOGY 
 Among the 3500 species of snakes fewer than 200 have been 
responsible for severe envenoming of humans, ending in death or permanent 
disability. Colubridae, the largest family of snakes, have been regarded as 
harmless, but an increasing number of species currently more than 40, are 
being recognized as capable of envenoming humans, in some cases fatally. 
Since the distinction between venomous and non-venomous species is 
uncertain, bites by any snake should be avoided and patients bitten by any 
species should be assessed carefully. 
 Regions free of venomous snakes include the Antartica, most of the 
islands of the western Mediterranean, Atlantic and Caribbean,  Madagascar, 
New Caledonia, New Zealand,  Hawaii and most of the other Pacific Islands, 
Ireland, Iceland and Chile. Elsewhere, venomous snakes are widely 
distributed upto altitudes of more than 5300 m (Agkistrodon Himalayans), 
within the Arctic Circle (Vipera berus), in the Indian and Pacific Oceans as 
far north as Siberia (Pelamis platurus), and in some fresh water lakes 
(Hydrophis semperi). 
 Snake bite is an important problem of the rural tropics; its incidence is 
usually underestimated because of the lack of reliable data. In the Indian 
 subcontinent, the most important species are cobra (Naja naja), common krait 
(Bungarus caeruleus), Russell’s viper (Daboia russellii) and Echis carinatus. 
 Most snake bites are inflicted on the lower limbs of farmers, plantation 
workers, herdsmen and hunters in the rural tropics7. Usually the snake is 
trodden on at night or in undergrowth. Some species such as the Asiatic kraits 
(Bungarus sp.) and African spitting cobras (N. nigricollis) enter dwellings at 
night and bite people who are asleep. Snakes do not bite without provocation, 
but this may be an inadverdent tread or touch. In Europe and North America, 
snakes are increasingly popular ‘macho’ pets : in these countries many bites 
are inflicted on the hands of people who are picking up the snake and in the 
United States, 25 per cent of bites result from snakes being attacked or 
handled. Serious bites by back – fanged (colubrid) snakes usually occur only 
under these conditions. 
 Seasonal peaks in the incidence of snake bite are associated with 
agricultural activities, such as ploughing before the annual rains in the West 
African Sahel and the rice harvest in southeast Asia, or to fluctuation in the 
activity or population of venomous snakes. Severe flooding, by concentrating 
the human and snake populations, has given rise to epidemics of snake bite in 
Pakistan, India, Bangladesh. Penetration of jungle areas during construction 
of new highways and irrigation and hydroelectric schemes has led to an 
increased incidence of snake bite. 
 Sea snake bites are an occupational hazard of fishermen in those parts 
of South–East Asia where hand nets are used. Mechanization of fishing 
methods has reduced the number of sea snake bites. The beaked sea snakes 
has caused most bites and deaths. 
Determinants of snake bite incidence  
1. Frequency of contact between snakes and humans depends on  a.
 Population densities 
 b. Diurnal and seasonal variations in activity 
 c. Types of behaviour (eg human agricultural  
activities). 
2. Snakes ‘irritability’ – (readiness to strike when alarmed or provoked) 
varies with species 
 
3.2 SNAKES AND THEIR FEATURES 
 Snakes belong to the Ophidia order of the Reptilia generic class. It is 
estimated that there are over 3500 species of snakes and about 250 of them 
are poisonous. The smallest snake is the Blind snake just a few inches long 
and the largest and heaviest is the Python Anaconda. It can grow upto 25 feet 
long and weigh as much as 300 pounds. It is important to identify snakes and 
to differentiate poisonous from non-poisonous snakes for initiating treatment 
 without delay. In India about 216 species are found, of which 52 are 
poisonous. 
 Among non-venomous snakes, only the giant constrictors (family 
boidoe) are potentially dangerous to man. There have been a number of fatal 
attacks by these snakes reported from Africa (rock python), South–East Asia 
(reticulated python) and South America. Some of the victims, even adults, 
were swallowed. 
 Snakes are classified morphologically by the arrangement of the scales, 
dentition, osteology, myology, sensory organs, the form of the hemipenes and 
increasingly by sequence analysis of DNA encoding important mitochondrial 
and other enzymes.   
 
Difference between Poisonous and Non- poisonous snakes1 
Feature Poisonous Non-poisonous 
Head Triangular  Rounded 
Pupil Elliptical  Rounded 
Belly Scales Large and cover entire 
breadth of belly (there are 
few exceptions) 
Small or moderately large but do 
not cover the entire breadth of 
the belly. 
Head Scales Small in viper, large with a 
pit between eye and nostril 
(pit viper) 
Larger 
Fangs  Long and grooved  Small and solid, ungrooved 
 Tail Compressed Not markedly compressed 
Habit Generally nocturnal Anytime 
Fang Marks Two long fang marks A number of small teeth marks 
in a row. 
General Features of Snakes 
 The snake bite is a quick, co-ordinated act of positioning of the head, 
opening the mouth, attacking by a forward thrust of the body and head, 
piercing the skin of the victim by the fangs and injecting the venom while the 
wound is deepened by the contraction of the temporalis muscle. The entire act 
occurs within seconds. Three African species and an Asian species (spitting 
cobra) can eject their venom from the tip of the fangs as a fine spray for a 
distance of few meters into the eyes of the enemy. Venom glands are behind 
the eyes surrounded by compressor muscles. A duct connects it to the fangs. 
2Venomous snakes can bite without injecting venoms. Approximately 20% of 
pit viper bites and an even higher percentage of bites inflicted by some other 
snake family are dry. (eg. upto 75% for sea snakes). The scales are distinctive 
in poisonous terrestrial snakes such as cobra, viper etc. A very thin skin 
covering the scales is cast off periodically. During the cast off process, a thin 
film covers the eyes also and snakes are blind until casting is complete. The 
mouth of the snake can be opened upto 180°. Curving inward teeth are present 
in the upper and lower jaw which helps the snakes to hold its prey and propel 
it into the mouth. The mobile fang of viper is usually tucked in and becomes 
erect before striking. Snakes are considered to have a very narrow tubular 
 vision. They are able to locate moving objects better than stationary ones and 
that explains the dancing of a cobra to the movement of a snake charmer 
playing the guard moving back and forth. Actually the snake is taking an aim 
to strike rather than dancing to the tune. Pit viper can detect even small 
temperature difference by their specialized pit. Elapidae inject venom by 
groove in the fangs while viperidae do so through tiny holes at the tip of the 
fangs. Russell’s viper is the most important cause of snake bite mortality in 
India3. Evidence of systemic involvement occurs within 30 minutes. 
 Classification of Snakes 
 The poisonous snakes may be divided into five families2. They are 
Elapidae, Hydrophidae, Viperidae, Atractaspididae and Colubridae. Some 
common species are 
Elapidae  : King cobra, Indian spectacled cobra,  
Egyptian cobra, Common Krait, Banded Krait, 
African Momba, Coral snakes 
Hydrophidae : Sea snakes 
Viperidae  : a. Sub family viperinae 
     Russell’s viper, saw scaled viper 
b. Sub family crotalinae 
     Pit viper, rattle snakes 
Atractaspididae : The burrowing asps. 
Colubridae : British Brass Snakes, Boom Slangs, Bird  
Snakes 
 Few characteristics of poisonous Indian snakes are discussed here for 
their identification. 
 
I ELAPIDS 
  Body is long, head nearly has the same width as of the neck. Pupils are 
rounded. Fangs are short, fixed and grooved so that it cannot penetrate 
clothing. 
1. Cobra 
 1.5 to 2 m long, usually black in colour. Head bears a hood with a 
spectacle mark. In the absence of hood, cobra can be identified by 2 – 3 series 
of very dark belly scales under and below the neck or by the divided tail 
scales. 
2. King Cobra 
 3 to 4 m long. The colour may be yellow, green, brown or black with 
white or yellow cross bands in the body. It has a hood but not a spectacle 
mark. Tail scales are full proximally but divided distally. Usually seen in 
jungles.  
3. Common Krait 
 1 – 1.5 m long, glistening black with single or double white arches in 
the back beginning some distance from the head. It has a central row of 
hexagonal scales on the back and creamy white belly features. Tail scales are 
full and not divided. 
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 4. Banded Krait 
 2 m long, usually alternative black and yellow bands are seen across its 
back. The tail ends bluntly and is swollen at the tip. 
II VIPERIDAE 
 The body is short with a narrow neck. Head is triangular and covered 
by small scales. Pupils are vertical. Fangs are long, mobile and grooved so 
that it can penetrate clothing. Pit viper’s envenomation are usually non fatal 
whereas pitless viper bites are fatal. 
1. Russell’s Viper 
 It is 1.5 m long, usually brown or buff coloured, and has 3 rows of 
diamond shaped spots on the back, with a narrow tortuous tail and divided 
scales. It has a short triangular head with distinct ‘v’ mark with the apex 
pointing forward. Its nostrils are bigger than that of other snakes. Its belly is 
white with broad scales. This species is usually seen in the plains. 
2. Saw Scaled Viper 
 It is 50 – 75 cm long, brownish grey or greenish in colour. It has a 
triangular head with a white mark resembling an arrow. Its  
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CORAL SNAKE 
 body has wavy lines on each flank with diamond  shaped marks between the 
lines. The scales on the head and body are small and scalded like a saw. Tail 
scales are not divided. 
3. Sea Snakes 
 They are black, greenish black or bluish black with or without bounds. 
It has a small head with a flat tail. Nostril is seen at the tip of snout valve. 
Belly plates are not broad, but dull and trabeculated scales in the back area are 
present. They have small feed fangs extending posteriorly. 
3.3 VENOM  AND THEIR EFFECTS 
 Venom produced by snakes is considered to be one of the most highly 
developed and complex of all toxins produced by plants or animals. The 
effects of snake venom of a particular species varies from snake to snake, 
from place to place, age of the snake and period of the year. The higher the 
altitude and lower the temperature, less toxic is the venom. Though the venom 
is found to be more viscid in summer, bites in months of November, 
December, January have increased morbidity and mortality which remains 
unexplained. The older the snake the more lethal the venom appears to be. 
Even though there has been a tremendous progress in identifying the 
 toxicological nature of venom, many questions remain unanswered and the 
complexity of the venom makes it a difficult subject to study. 
Venom fulfills three main functions.4 
- Immobilization of prey 
- Digestion of prey. 
- Deterrence of predators 
Snake venoms are chemically complex mixtures of protein ranging  
from 6 to 100 KD.5 
Venom is an enzyme made of peptides and polypeptides. Elements 
such as Zn, Mg have been separated from snake venom. It has been observed 
that the in vitro effect of the venom may not be seen in vivo. Some of the 
proteolytic enzymes arginine hydrolase, collagenase and hyaluronidase help 
in spreading of venom into tissues. Acetylcholine esterase present in cobra 
venom plays an important role in the generation of neuroparalytic symptoms. 
 Cobra venom contains neurotoxin, haemolysin, cardiotoxin, 
cholinesterase and nucleotidase.  
 Viper venom contains hyaluronidase, haemolysin, heamorrhagin and 
phosphorylase. 
ENZYME COMPONENTS OF SNAKE VENOM 
 Enzyme     Effects 
 Arginine esterhydrolase  Bradykinin release interferes with  
    clotting  
Proteolytic enzymes  Tissue destruction, causes bleeding  
Collagenase    Digestion of collagens 
Hyaluronidase A   Reduction of collagen viscosity 
Phospholipase A   Uncoupling of  
     oxidative phosphorylation 
Acetyl cholinesterase  Hydrolysis of Acetylcholine 
Nucleotidase   Specific hydrolysis of phosphate    
   monoesterase which links with 5th     
   position of DNA, RNA 
Thrombin like enzymes  Depression of fibrinogen levels. 
Cobra venom components are smaller molecular weight substances 
which are absorbed rapidly into blood. Viperid toxins are large molecular 
weight substances which are absorbed through lymphatics and have a slower 
onset of action. 
NON ENZYME COMPONENTS OF SNAKE VENOM 
Neurotoxin (Elapidae) Post synaptic non depolarizing 
 neuromuscular blockade of long duration acting 
only on Nicotinic Ach receptors 
Cerulotoxin Post synaptic block but without binding to 
receptors 
Haemorhagins Direct disruption of vessel endothelium 
(Viperidae, Crotalinae) Factor IX activation by cleavage of peptide bond 
in factor IX by Russell’s viper venom. 
 Factor X activation to factors Xa by calcium 
binding to gamma glutamic residues in factor X.  
 Direct prothrombin activation 
 Prolonged defibirnation even without 
thrombocytopenia in Echis carinatus 
 Inhibition of platelet aggregation, clotting factors 
activation, fibrinolysis or fibrinogenolysis by 
direct action on plasminogen. 
 LETHAL DOSE OF VENOM6 
Snake Lethal Dose 
Cobra 12mg 
Russell’s viper 15mg 
Krait 6mg 
Saw scaled viper 15mg 
 
PATHOGENESIS 
Broad classification of snake venom activities4 
Toxin activities type Clinical effects 
Neurotoxin presynaptic  Flaccid paralysis 
Presynaptic Resistance to late antivenom therapy  
Postsynaptic Often reversal with antivenom therapy 
Anticholinesterase Fasciculation 
Myotoxin Systemic skeletal muscle damage 
Hemostatic system toxins Interferes with normal hemostasis 
causing either bleeding  or thrombosis 
Hemorrhagins Damage vascular wall causing bleeding  
Nephrotoxins Direct renal damage 
Cardiotoxins Direct cardiotoxicity 
Necrotoxins Direct tissue injury at the bite site / bitten 
limb 
 
a. Neurotoxicity 
 This is the predominant feature in bite of Elapids. Symptoms can occur 
from few minutes to 4-6 hours later. The effect of neurotoxin is strictly at the 
peripheral level only, on the neuro muscular junction blocking the Ach 
receptors. Muscles supplied by cranial nerves are affected first resulting in 
ptosis, dropping of head, paralysis of pharyngeal muscles, dysphonia followed 
by respiratory muscle paralysis. 
b. Cytotoxicity 
Tissue edema, bullae, necrosis and ulceration caused by viper and 
some cobra bites are due to cytotoxic components of venom. Rhabdomyolysin 
in sea snake venom causes extensive necrosis of striated muscle which can 
lead to myoglobinuria and renal failure. The protease and hyaluronidase also 
contributes to local cytotoxic reaction. 
c. Cardiotoxicity 
Cardiac rhythm abnormalities, non specific ECG changes, hypotension 
and cardiac arrest are all attributed to cardiotoxic venom component. It is seen 
in envenomation due to puff adder, pit viper and rattle snake. In certain cobra 
bites cardiac arrest precedes respiratory failure 
d. Haemotoxicity 
The haematological7 abnormalities are attributed to anticoagulants, 
procoagulants, fibrinolysin, haemorrhagin and haemolysin in the venom. 
 Bleeding tendency seen commonly in viper bites is due to vascular 
endothelial damage caused by haemorrhagin fragment of venom. Anemia is 
due to haemorrhage and microangiopathic anemia due to entrapment of red 
blood cells in fibrin in DIC. Hemolysis is due to phospholysin which converts 
red blood cell lecithin to hemolytic substance lysolecithin. Evidence of 
complement mediated hemolysis has been described in cobra venom. 
e. Nephrotoxicity 
Most snake venoms are concentrated and excreted through the kidneys. 
Very rapid development of oliguria seen in some patients supports the idea of 
massive occlusion of renal microvasculature with fibrin. Loin pain and renal 
angle tenderness could be a manifestation of renal ischaemia. Heavy 
protinuria and red cell casts in urine imply glomerular damage 
Direct nephrotoxic effects of venom are not known. Apart from the 
above mechanism haemorrhagic shock, hypovolemic shock and 
myoglobinuria can cause acute renal failure. 
Others 
Angioedema, abdominal pain, vomiting and diarrhea can occur as a 
hypersensitivity reaction to venom. Sudden collapse and hypotension is due to 
vasodilator susbstance in venom, endogenous histamine and serotonin release. 
INTERVAL BETWEEN THE BITE AND TIME OF DEATH 
 Snakes Range  Mean 
Cobra 30 min – 60 hrs 8 ½ hrs 
Krait 3 – 68 hrs 18 hrs 
Russell viper 2 hrs – 9 days 3 days 
Echis carinatus 1 – 41 days 5 days 
Sea snakes 12 – 24 hrs Variable 
Causes of Death  
Death in snake bite is due to 
1. Paralysis of respiratory muscles 
2. Upper airway obstruction 
3. Cardiac arrest 
4. Hypotension and shock 
5. Severe bleeding including intracranial bleed 
6. Renal failure 
7. Septicemia 
3.4 CLINICAL FEATURES 
There are few features which modify the clinical features in an 
envenomation. They are:  
i Age 
 Children are more seriously affected as venom dose per body mass is 
more than adult and the circulating extra cellular fluid volume is also low. 
These factors cause rapid rise and greater concentration of venom in children. 
ii Bite  
a. Location 
b. Depth 
c. Number of bites 
d. Duration of time the snake holds on the bite. 
 
iii Venom glands 
Empty glands in the snake suggests recent strike. 
iv Fangs 
Broken fangs in a snake indicate successful bite. 
v Venom  
i. Dose of venom injected – depends on mechanical efficiency of bite, 
species and size of the snake. 
ii. Composition and hence potency of venom – depends on species and 
within a species the geographical location, season and age of the snake. 
 vi Efficacy of first aid 
More prompt and appropriate the first aid, the less severe the 
symptoms. 
SIGNS AND SYMPTOMS 
 Fear and anxiety are common symptoms. Extreme reactions of fright, 
anxiety and hysterical reactions do occur commonly. It is important to 
differentiate the symptoms of anxiety, fear, fright and hysterical reactions 
from actual symptoms of envenomation. 
 Dizziness and light headedness occur in both poisonous and non-
poisonous snake bites. These are not necessarily psychological symptoms. 
Nausea, vomiting and abdominal pain are very common in any form of 
envenomation. This may be due to submucosal haemorrhage in the gastro 
intestinal tract. 
Local Area of Bite 
 Local pain is very common and the severity of the pain is not related to 
systemic envenomation. Pain may start immediately or few hours later. It can 
last from 24 hours to 72 hours. It is felt that thrombosis of the terminal 
arterioles at the bite site could be the cause of the excruciating pain. Swelling 
at the bite site is typical of envenomation (a poisonous bite). It can occur 
within 15 minutes of a bite and progress to enormous size in 72 hours. 
Beyond that it starts subsiding slowly. Swelling is due to direct cytotoxic 
 effects. Swelling, blistering, necrosis and proximal extension are seen in both 
cobra and viper bites but purulent inflammation and coagulation necroses are 
common in Elapid bites. Necrosis and ulceration can occur at bite site due to 
direct venom effect. Necrotic area may get secondarily infected with bacteria. 
 Local swelling is invariably a feature of envenomation, based on which 
treatment with ASV can be started even in the absence of neurotoxic or 
haemotoxic symptoms. 
Bleeding Manifestation 
 It is the primary effect of viper bite. Bleeding gums, haemoptysis, 
haematemesis, haematuria, malena, epistaxis, ecchymosis and purpura are 
signs of haemotoxicity. Bleeding gums is very common. Early bleeding is due 
to haemorrhagin activity. Late onset bleeding (after 24 – 72 hours) may be 
due to DIC. Case presenting as pleuropericardial haemorrhage has been 
documented9. 
Complement Activation46  
 Elapid and some colubrid venom activate complement via the 
alternative pathway whereas some viperid venoms activate the classical 
pathway. Complement activation may in turn affect platelets, the blood 
coagulation system and other humoral mediators.47 
Renal System 
  Victims of viper bite have early proteinuria. Proteinuria is reported 
much earlier than blood coagulation abnormalities. Microscopic haematuria 
occurring in first 24 – 48 hours is seen commonly in viperid bites. Patients 
presenting with renal angle tenderness at the early stages need to be watched 
for renal shut down. Acute renal failure can occur. 
Shock 
 Shock due to haemorrhage, hypovolemia, direct cardiotoxicity or 
vasomotor centre dysfunction caused by DIC is an important cause of 
mortalilty. 
Central Nervous System Symptoms and Signs  
 In Elapid bites the neuroparalytic symptoms develop from 30 minutes 
to 10 hours after bite. Ptosis is the earliest feature followed by 
ophthalmoplegia, paralysis of respiratory muscles and limb muscle weakness. 
Confusion due to hypoxia is a risk factor for mortality. Convulsions are 
common in krait envenomation. 
 In viperid bites neurological symptoms are due to thrombosis10,11,12 or 
haemorrhage of the intracranial vasculature. Subarachnoid haemorrhage and 
intracerebral haemorrhage are known to occur in viperid bites. 
 Acute paraplegia has also been documented following viper bite13. 
 All the neurotoxic symptoms due to Elapid bites are reversible if early 
and adequate treatment is instituted. Neurotoxicity, vomiting14 and serum 
creatitine level are significant predictors of mortality among patients with 
snake bite. 
Cardiovascular System Symptoms and Signs  
 Tachycardia, arrhythmias, frequent ventricular premature complexes, 
ST-T changes in the ECG are rarely seen in viperid bites. Cardiac failure 
occurs rarely. 
 The reason for lethal arrhythmias in viperid bites is due to 
hyperkalemia as a result of hemolysis and haemorrhage. Hyperkalemia should 
be identified and treated early. Case presenting as acute myocardial 
infarction12,15 has been documented. 
Opthalmological Symptoms and Signs 
 Apart from neuro-ophthalmological symptoms of Elapid bites, edema 
of the lids, conjunctiva, periorbital edema, ecchymosis, subconjunctival 
haemorrhage, retinal artery thrombosis and keratitis can occur with viperid 
bite. These symptoms usually respond to treatment. 
 
Venom Opthalmia39,41 
  Venoms of the spitting cobras and ring kals are intensely irritant and 
even destructive on contact with mucous membranes such as the conjunctiva 
and nasal cavity. Corneal erosions, anterior uveitis and secondary infections 
may occur. Secondary infection of the corneal lesion may result in permanent 
opacities, causing blindness or panopthalmitis, with destruction of the eye. 
Bites By Sea Snakes40,42,43 
 The bite is usually painless and may not be noticed by the wader or 
swimmer. Teeth may be left in the wound. There is minimal or no local 
swelling and involvement of local lymph nodes is unusual. Generalised 
rhabdomyolysis is the dominant effect of envenoming by these snakes. Early 
symptoms include headache, a thick feeling of the tongue, thirst, sweating and 
vomiting. Generalized aching, stiffness and tenderness of the muscles become 
noticeable between 30 min and 3½ hours after the bite. Trismus is common. 
Passive stretching of the muscles is painful. Later there is progressive flaccid 
paralysis starting with ptosis. Myoglobinaemia and myoglobinuria develop 3-
8 hours after the bite. These are suspected when the serum or plasma appears 
brownish and the urine is  dark reddish brown. Myoglobin and potassium 
released from damaged skeletal muscles may cause renal failure, while 
hyperkalemia developing within 6-12 hours of the bite may precipitate cardiac 
arrest. 
3.5 MANAGEMENT 
Lab Investigations 
  It may show progressive anemia, polymorphonuclear leucocytosis 
(20,000–30,000/mm3), thrombocytopenia, hypo-fibrinogenemia, increased 
clotting time, proteinuria, haematuria and azotemia16. 
 Anemia results from bleeding or rarely from hemolysis. Malayan pit 
vipers and saw scaled viper bite produce thrombocytopenia secondary to DIC. 
 An useful test for venom induced haemotoxicity is the clot quality 
test48,49. A few ml of blood is collected in a clean dry glass test tube, left 
undisturbed for 20 minutes and then tipped to assess clotting. The tube is then 
again examined after 12 hrs to assess the size of the clot. Non-clotting may be 
a pointer towards systemic envenomation. 
 ECG changes of hyperkalemia, arrhythmias and heart block may be 
seen. ECG in viper bite may show inverted T waves, ST segment elevation, 
prolonged QT interval and arrhythmias. 
 Urine Analysis for haemoglobin and myoglobin are done when it is 
high coloured. Microscopic haematuria, tubular and granular casts might be 
seen in urine examination. 
 Chest radiographs are useful for detecting pulmonary edema (European 
vipera), pulmonary haemorrhage, infarct, pleural effusion and secondary 
bronchopneumonia (Dabia russelli). 
Immuno Diagnostic Tests36 
  Specific snake venom antigens have been detected in wound aspirates, 
blood, urine, CSF and other body fluids by using immuno diffusion method, 
counter current immuno electrophoresis, Radio immuno assay, passive 
hemeagglutination and ELISA17, 18, 50, 51 . ELISA is the simplest and most 
sensitive test. The species responsible and the level of envenomation can be 
accurately established. These tests are not routinely used. They are used for 
research purposes and for forensic purposes, in confirming the cause of deaths 
suspected to have been caused by snake bite. Venom antibodies may be 
detected by ELISA upto many years after the bite. 
 TREATMENT 
 The treatment of snake bite consists of 
1. First aid. 
2. Medical treatment of envenomation. 
3. Supportive Measures.  
First Aid 
Reassurance in all cases of snake bites is very important. The site of 
the bite should be lightly wiped and covered with a clean piece of cloth. A 
firm (but not tight enough to be vaso occlusive) knot should be applied just 
above the bite using a cloth. Making incisions, suction of wound, cooling the 
bite site, applying electric shocks, acid cauterization of wound should never 
be done as a first aid measure as these increase the chances of infection. The 
bitten part should be splinted if possible and kept at approximately heart level. 
With the first aid treatment, the victim should be rushed to the nearest 
hospital. If the snake has been killed it should be taken to the hospital for 
identification by the treating doctor. 
 TREATMENT OF ENVENOMATION 
Polyvalent antisnake venom 
 This serum is prepared by hyper immunizing horses against the venom 
of the four common poisonous snakes. i.e. cobra, common krait, Russell’s 
viper, and saw scaled viper. Plasma obtained from the hyperimmunised horses 
is concentrated and purified. The serum is lyophilised by drying it to the 
frozen state under high vaccum. It is prepared in the Haffkine Institute 
Mumbai, King Institute Chennai, Serum Institute Pune and at Kasauli in India 
and is available in the form of lyophilized powder in an ampoule which 
retains potency for ten years. It is dissolved in distilled water or normal saline 
and administered as an infusion in 500 ml of saline at 15 to 20 drops per 
minute. 
 Antivenom therapy19 is indicated if the following features are present: 
i) Signs of local envenomation – Rapidly progressive extensive local 
swelling. 
ii) Symptoms / signs of neurotoxicity 
iii) Symptoms / signs of haemotoxicity 
 
iv) Increased clotting time 
v) Signs of cardiotoxicity – hypotension 
vi) Bites on digits by snakes with known necrotic venoms 
 Amount of venom neutralized by 1 ml of polyvalent ASV20 is known. 
Cobra   0.6 mg 
 Russell’s viper 0.6 mg 
 Krait    0.45 mg 
 Echis Carinatus  0.45 mg 
 Incidence21 of complications was directly proportional to the duration 
of venom in the blood. The early institution of ASV is beneficial in 
preventing complications, however severe the systemic envenomation. Anti 
snake venom (ASV) can effectively reverse systemic poisoning even if it is 
given hours or days after the bite. 
 It is never too late to start ASV. ASV administration is found to be 
useful even after 2 days of bite if systemic signs of envenomation are still 
present. Anandha Padmanaban. J has described the usefulness of late 
administration of ASV23. 
 It is advisable to give intradermal test dose of 0.2 ml of 1:10 diluted 
ASV and watch for 10 minutes for any allergic reaction. If there is no 
reaction, ASV can be administered. 
 But reactions do appear while ASV is given as an infusion inspite of 
negative skin testing. On the contrary cases have been reported, where inspite 
of a positive skin test ASV was subsequently infused without any reaction. 
  Studies22 show that the level of ASV reactions varies between 3-54%. 
These reactions are treated with 0.5 ml of intra muscular adrenaline, 
supported by 100mg hydrocortisone and 10 mg of anti-histamine at the first 
sign of reaction. 
 If life saving, ASV should be given inspite of a positive skin test. In 
such cases benefits out weigh the risks. In such circumstances ASV infusion 
and adrenaline infusion should be given in parallel. Alternatively 250 mg of 
methyl prednisolone sodium succinate in 1000 ml of 5% dextrose can be 
given along with ASV. 
 Dosage of ASV is a subject of great controversy. A dosage of  
100 ml for cellulitis and mild systemic toxicity and a dosage of  
200 ml for severe systemic toxicity is recommended. Advantage is achieved 
in large dosage. Few authors recommend ASV till there is clinical or lab 
parameter improvement (clotting time). 
 The dosage of ASV in viperid bites can be adjusted according to 
clotting time estimation and the type of clot formed. In Elapid bites it has to 
be based on clinical observation and ASV is continued till neuroparalytic 
signs clear. 
 Neurotoxic signs improve within 30 minutes to few hours after 
initiation of ASV. Spontaneous systemic bleeding stops within 15 – 
30minutes and clotting time becomes normal within 6 hours of starting ASV. 
 More ASV is required if clotting time does not normalize after 6 hours. Half 
life of ASV is 26 – 95 hours. 
ANTIVENOM REACTIONS 
 Antivenom treatment may be complicated by early (anaphylactic), 
pyrogenic and late (serum sickness type) reactions. 
Early Antivenom Reactions 
 Cannot be predicted by hypersensitivity tests. The complement system 
is probably activated by aggregates of IgG. Reactions usually develop within 
10-180 minutes of starting antivenom. There is itching, urticaria, fever, 
tachycardia, palpitation nausea, vomiting and cough. Upto 40% of patients 
show features of severe systemic anaphylaxis, bronchospasm, hypotension or 
angioedema. Treatment is done with adrenaline and chlorpheniramine 
maleate. 
Pyrogenic Reactions  
 Results from contamination of the antivenom by endotoxin like 
compounds. High fever develops 1-2 hours after treatment and is associated 
with rigors followed by vasodilatation and a fall in blood pressure. Patients 
should be cooled and given antipyretics by mouth, powdered and washed 
down a nasogastric tube or by suppository. 
Late (Serum Sickness Type) Reactions 
  This reaction develops 5-24 days after treatment. Their incidence and 
speed of development increase with the dose of antivenom. Symptoms 
include fever, itching, urticaria, arthralgia, lymphadenopathy, periarticular 
swellings, mononeuritis multiplex, albuminuria and rarely encephalopathy. 
This reaction responds to an antihistamine such as chlorpheniramine or in 
more severe cases to steroids. 
 Rarely myelopathy24, acute pulmonary edema25, fatal acute 
disseminated26 encephalomyelitis following ASV administration has been 
documented. 
SUPPORTIVE MEASURES 
Severe blood loss 
 Whole blood transfusion is restricted to cases of severe blood loss. 
Fresh frozen plasma transfusion not only replenishes the fibrinogen but also 
the other depleted clotting factors. 
Shock 
 Large – bore intravenous access in unaffected extremities should be 
established. Promptly treated by intravenous fluid and electrolyte 
administration. In neurotoxic cases, electrolyte imbalance can be corrected by 
normal saline or 5 percent glucose saline. In severe hypotension, the use of 
vasopressors (dopamine) and corticosteroids in usual doses are recommended. 
 Pain 
 Paracetamol can be used for pain. A mild sedation with diazepam or 
phenobarbitone can be given to patients, if needed. 
 
Respiratory Failure 
 Oxygen should be given. A tracheostomy or oxygen through 
endotracheal intubation may be indicated. Hyperbaric oxygen therapy has 
been reported to be of value in neurotoxic poisoning. Most of the  patients 
need ventilatory support. 
Renal Failure 
 Renal failure can be prevented by blood replacement and pervention of 
shock. In case of renal shut down beneficial results have been seen with 
peritonial as well as hemodialysis. Dialysis and supportive27 treatment 
appears to be the mainstay of therapy in cases complicated by renal failure. 
Neuro Paralysis 
 The best results are obtained by starting neostigmine28,29 as soon as the 
neurological signs appear and it is essential to continue neostigmine till the 
complete neurological recovery is made, otherwise premature discontinuation 
may lead to relapse of neuroparalysis. Each dose of 0.5 mg  neostigmine is 
preceded by an injection of 0.6 mg of atropine sulphate. 
 
 To prevent tetanus 
 Tetanus toxoid booster dose and tetanus immunoglobulin of human 
origin should be given. 
Secondary infection 
Secondary infection can occur in the bite site region. So proper 
antibiotics should be used to prevent secondary infection. 
Local complications 
 Local complications31 are frequent but can be managed conservatively. 
Delayed excision of the resultant local necrosis is associated with good 
outcome. The need for fasciotomy is  rare. 
Snake Venom Opthalmia 
 The spat venom should be washed from the eye or mucous membrane 
as soon as possible using large volumes of water or other bland fluid. Topical 
antimicrobial agent should be applied for corneal abrasions. Adrenaline 
eyedrops (0.1%) relieve pain.  
Heparin30,44,45 
 Heparin seems to be having beneficial role which need to be confirmed 
by larger trials and longer duration of heparin administration in disseminated 
intravascular coagulopathy like condition. 
  Whether or not antivenom is given, any patient with signs of venom 
poisoning should be observed in the hospital for atleast 24 hours. A patient 
with an apparently dry bite should be watched for at atleast 8 hr before 
discharge as significant toxicity occasionally develops after a delay of several 
hours. The onset of systemic symptoms is commonly delayed for a number of 
hours after bites by several of the elapids and sea snakes. Patients bitten by 
these reptiles should be observed in the hospital for 24 hr. Any patient 
requiring antivenom treatment should be admitted in an intensive care setting. 
Follow Up Care2 
 Follow up care should include referral for physiotherapy when needed 
to return the patients to an optimal level of functioning. In addition, victims of 
viperid bite should be reevaluated for evidence of recurrent coagulopathy 48 
hours after discharge and as needed thereafter. These patients should be 
warned to avoid any elective surgery for the first few weeks as occult 
coagulopathy can recur. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials & 
Methods 
 MATERIALS AND METHODS 
 
STUDY POPULATION 
 56 patients  with history of snake bite admitted in the intensive care 
unit of Government Royapettah Hospital, Kilpauk Medical College during the 
period from Jan 2005 to Dec 2005 were taken up for the study. 
SELECTION CRITERIA 
 Patients presenting with the history of snake bite with or without 
evidence of bite were taken up for the study. Patients with history and 
definitive evidence of snake bite in the form of local cellulitis, regional 
lymphadenitis, prolonged clotting time, neurotoxic manifestations like ptosis, 
dysphagia, external opthalmoplegia and respiratory failure were included in 
the study under venomous group. Patients with history of snake bite with or 
without local swelling with normal clotting time were considered under non 
venomous group. Patients having local swelling due to tourniquet application 
and local native treatment were also considered for the study. 
 Complete history was elicited in all the cases. Detailed clinical 
examination was done in all the cases. Available necessary investigations 
such as complete haemogram, bleeding time, clotting time, renal function 
 tests and urine routine were done. Complications encountered and effective 
management given are compiled, compared and presented in this study. 
  
 
 
 
 
 
 
 
 
 
 
 
Results of the Study 
 RESULTS OF THE STUDY 
TOTAL NUMBER OF SNAKE BITE CASES STUDIED  
56 CASES 
TABLE - 1 
AGE DISTRIBUTION 
S.No. Age in Years No. of cases  
1 11 – 20 8 (14.28%) 
2 21 – 30 22 (39.28%) 
3 31 – 40 13 (23.21%) 
4 41 – 50 6 (10.7%) 
5 51 – 60 6 (10.7%) 
6 > 60 1 (1.8%) 
Mean ± SD 
32.80357 ± 12.77842 
 The mean of the age distribution is 32.80 years and the maximum 
number of cases are in age group 21 – 30 years (39.28%) 
TABLE - 2 
GENDER DISTRIBUTION 
Sex Number of Cases 
Male 42 (75%) 
Female 14 (25%) 
  
 TABLE - 3 
SEASONAL INCIDENCE (MAXIMUM PERCENTAGE OF CASES IN 
A SINGLE MONTH) 
Months Number of Cases 
May 05’(1st Maximum) 9 (16%) 
August 05’ (2nd Maximum) 8 (14.28%) 
 
TABLE - 4 
OCCUPATIONAL INCIDENCE 
Occupation Number of Cases 
Manual Labourers 26 (46.4%) 
Farm Workers 14 (25%) 
Gardeners 5 (8.9%) 
Sewage Workers 4 (7.14%) 
Vendors 3 (5.35%) 
School Children 2 (3.57%) 
Others 2 (3.57%) 
 TABLE - 5 
INDOOR / OUTDOOR DISTRIBUTION OF SNAKE BITE 
Place Number of Cases 
Outdoor Bites 48 (85.7%) 
Indoor Bites 8 (14.3%) 
 
 
TABLE - 6 
TIME OF BITE 
Time Frame Number of Cases 
6 AM to 12 Noon 15 (27%) 
12 Noon to 6 PM 11 (19.7%) 
6 PM to 6 AM 30 (54%) 
 
 TABLE - 7 
SITE OF BITE 
Site Number of Cases 
Lower Limb 43 (76.79%) 
Upper Limb 12 (21.42%) 
Trunk 1 (1.8%) 
 
 
TABLE – 8 
TIME LAG BETWEEN SNAKE BITE AND  
HOSPITALIZATION  
Time lag Number of Cases 
<1 Hours 7 (12.5%) 
1 – 2 Hours 21 (37.5%) 
2 – 3 Hours 15 (26.8%) 
3 – 4 Hours 6 (10.7%) 
4 – 6 Hours 2 (3.57%) 
> 6 Hours 5 (8.92%) 
 
 
 
 
TABLE - 9 
 REGIONAL DISTRIBUTION OF SNAKE BITE 
Place Number of Cases 
Urban Area 37 (66%) 
Suburban Area 19 (34%) 
 
  
TABLE – 10 
SIGNS OF LOCAL ENVENOMATION 
Sign Number of Cases 
Fang Marks 49 (87.5%) 
Immediate Pain 46 (82%) 
Rapid Swelling 14 (25%) 
Necrosis / Ulceration 4 (7.14%) 
Bullae 3 (5.35%) 
Paraesthesia 1 (1.8%) 
Petechiae - 
 
 
 
SIGNS AND SYMPTOMS OF SYSTEMIC ENVENOMATION 
 
 TABLE - 11 
NEUROTOXICITY - 3 CASES (5.35%) 
Symptoms and signs  Number of Cases 
Ptosis 3 (5.35%) 
Ophthalmoplegia 3 (5.35%) 
Resp. paraysis 2 (3.57%) 
Flaccid limb paralysis - 
 
 
TABLE - 12 
HAEMOTOXICITY - 22 CASES (39.28%) 
Symptoms and Signs Number of Cases 
Clotting Time increased 22 (39.28%) 
Microscopic Haematuria 12 (21.4%) 
Bleeding from Bite Site 4 (7.14%) 
Bleeding from gums 2 (3.57%) 
Haemoptysis 1 (1.8%) 
Haematemesis - 
Epistaxis - 
 
 TABLE - 13 
CARDIOTOXICITY - 4 CASES (7.14%) 
Manifestations  Number of Cases 
Hypotension 4 (7.14%) 
ECG Changes 3 (5.35%) 
  
 
TABLE - 14 
NATURE OF TOXICITY 
Type of Toxicity Number of Cases 
Haemotoxicity 22(39.28%) 
Neurotoxicity 3(5.35%) 
Cardiotoxicity 4 (7.14%) 
Haemotoxicity only 20 (35.7%) 
Neurotoxicity only 1(1.78%) 
Combined haemotoxicity and 
Neurotoxicity 2(3.57%) 
Cellulitis and haemotoxicity 14(25%) 
Haemototoxicity and Cardiotoxicity 3 (5.35%) 
Neurotoxicity and Cardiotoxicity 1 (1.78%) 
No Envenomation 33(59%) 
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 TABLE – 15 
 
SNAKES IDENTIFIED 
TOTAL NUMBER OF DEAD SNAKES BROUGHT BY ATTENDERS - 
4 
Type of Snake Number of Cases 
Viper 3 (5.35%) 
Krait 1 (1.78%) 
Cobra - 
 
INVESTIGATIONS 
TALBE – 16 
CLOTTING TIME 
Clotting Time Number of Cases 
<10 minutes 34 (60.7%) 
10-20 minutes 12 (21.4%) 
20-30 6 (10.7%) 
> 30 4 (7.14%) 
Mean ± SD 
11.85714 ± 9.260726 
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 TABLE – 17 
HAEMOGLOBIN ESTIMATION 
Haemoglobin gm/dl Number of Cases 
< 7 2 (3.57%) 
7 – 9 - 
9 – 10 1 (1.8%) 
> 10 53 (94.6%) 
Mean ± SD 
12.1125 ± 1.54967 
The  mean of  haemoglobin estimation in our study is 12.1125. 
TABLE – 18 
WHITE BLOOD CELLS ESTIMATION 
WBC / mm3 Number of Cases 
4000-9000 26 (46.4%) 
9000-11000 30 (53.6%) 
 
TABLE - 19 
PLATELET COUNT 
Platelet Count Number of Cases 
1- 1.5 lakhs / mm3 18 (32.14%) 
> 1.5 lakhs / mm3 38 (67.9%) 
TABLE - 20 
 URINE ROUTINE 
Deposits Number of Cases 
Microscopic haematuria 12 (21.4%) 
Tubular and Granular Casts 1(1.78%) 
 
TABLE – 21 
RENAL PARAMETERS ESTIMATION  
Renal Parameters 
Blood Urea mg/dl Serum creatinine 
mg/dl 
Number of Cases 
≤ 40 ≤ 1.2 53 (94.6%) 
> 40 > 1.2 3 (5.4%) 
 
TABLE - 22 
ECG 
ABNORMAL ECG WAS SEEN IN 4 PATIENTS. 
ECG Changes Number of Cases 
Sinus Bradycardia 1 (1.78%) 
ST-T Changes 3 (3.57%) 
 
TABLE - 23 
 TREATMENT 
ASV Administered 23 cases (41.7%) 
ASV Not administered 33 cases (58.3%) 
 
Minimum dose of ASV  : 30 ml  
Maximum dose of ASV  : 160 ml 
Reaction to ASV    : 3 cases  (5.35%) 
Antibiotics 
 Broad spectrum antibiotics were given in patients with local cellulitis. 
Neostigmine 
 Administered in all 3 cases of neuroparalysis at a dose of  
0.5 mg half hourly till improvement. 
 Each dose of neostigmine was preceded by an intravenous  injection of 
0.6 mg of atropine sulphate. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TREATMENT
ASV Administered  
42%
ASV Not administered
58%
 Steroids 
 Hydrocortisone 100 mg intravenous was administered in 3 cases who 
developed reaction to ASV and in 4 cases who presented with shock. 
Mechanical Ventilation 
 Mechanical ventilation with endotracheal intubation was given to two 
patients who had respiratory paralysis. 
Peritoneal Dialysis 
 Of the three patients who had renal failure only one patient was treated 
with peritoneal dialysis. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
 DISCUSSION 
 In our hospital, we received 56 cases of snake bite during the period 
from January 2005 to December 2005. 66% of these patients were from urban 
area and the rest 34% were from suburban area. The increased incidence of 
cases reported from urban area can be attributed to rapid urbanization, 
bringing increasing areas of uninhabited lands under human colonization. 
Cases from suburban areas may not have reported to our hospital because they 
would have opted either native treatment or would have been treated by local 
practitioners. This would have been the reason for the less number of cases 
from suburban areas. Though the number of snake bite cases were few in 
urban areas in comparison to that of suburban area almost all patients form 
the urban area invariably reported to the hospital because of the awareness of 
the availability of specialized and specific management for snake bite. 
 While snake bite was observed in all age groups, the largest majority 
were found in the age group of 21 – 30 yrs. (39%). This is in accordance with 
the study conducted at SCB Medical College Hospital, Cuttack32 and Calcutta 
School of Tropical Medicine.35  
 The sex distribution shows males and females affected in the ratio of 3 
: 1. The incidence of 75% in males and 25% in females more or less concurs 
with the study of JIPMER33 Hospital which has found 68% incidence in males 
and 32% incidence in females. The study conducted in PGIMER Hospital34, 
Chandigarh showed the incidence among male and female to be 4.25:1. 
  The occupational incidence showed that urban victims were 
predominatly constructional workers whereas victims from suburban areas 
were predominantly farmers. 
 Nearly 86% of bites were reported from outdoor areas suggesting that 
the reptiles do not commonly ingress the human dwelling.  
 Seasonal incidence in our study showed that the maximum incidence in 
a single month was in May 2005 (16%) followed by August 2005 (14.28%). 
This observation suggests that the higher incidence of snake bite in the month 
of May and August is closely related to seasonal changes which compels the 
reptiles to come out of their shelter. Similar observation of increased 
incidence in May was observed in study at PGIMER Hospital Chandigarh34. 
 Regarding diurnal incidence 46% of bites occurred between 6 AM to 6 
PM and 54% occurred between 6 PM and 6 AM. In the study at PGIMER 
Hospital Chandigarh34, the incidence of bites at night was 60.6% which is 
more or less equal to our study. 
 The bite site incidence was 76.8% in the lower extremity and 21.42% 
in the upper extremity suggesting that the lower extremity was frequently 
involved. Bite site in lower extremity was commonly seen in the feet, and in 
the upper extremity fingers were commonly involved. Only one case (1.8%) 
of snake bite in the trunk area was encountered. This observation is also 
similar to that made at PGI MER Hospital, Chandigarh where the most 
 common site involved was the feet 8%). The most frequent sites of bite being 
in the feet and fingers clearly indicates that the site of bite is predominantly 
determined by accidental or inadvertent contact of the reptile during activities. 
 It is difficult to estimate accurately the incidence of poisonous snake 
bites. However in clinical practice efforts are made to identify the offending 
snake from the presenting symptomatology. While such an approach may 
give sufficient clues to the incidence and types of envenomation, there may be 
an indeterminate number of cases where the actual bite was inflicted by 
poisonous varieties without envenomation. 
 The cardinal findings of snake bite envenomation include fang marks, 
immediate pain and rapid swelling. Immediate pain showed up in 82% of 
cases, fang mark was noticed in 87.5% of cases and rapid swelling seen in 
25% of cases. Bullae was noticed in 5.35% of cases. Necrosis and ulceration 
were noticed in 7.14% cases. Paraesthesia was there in 1 case. Petechiae was 
not observed in any case. 
 In our study 3 patients had symptoms of neurotoxicity. Ptosis was seen 
in all 3 patients, respiratory paralysis in 2 patients and  ophthalmoplegia in all 
3 cases. 
 Symptoms, signs and lab evidence of haemotoxicity was observed in 
22 patients. All 22 had increased clotting time. Microscopic haematuria was 
 present in 12 cases. Bleeding from bite site was seen in 4 cases. Bleeding 
gums was observed in 2 cases. 
 Of the various investigations done, clotting time proved to be the best 
indicator of haemotoxicity. 
 Acute renal failure developed in 3 cases who had signs of 
haemotoxicity. 
 A combination of both haemotoxicity and neurotoxicity was present in 
2 of our cases. 
 Signs of cardiotoxicity were present in four of our cases.  
 Signs of local envenomation (cellulitis) with haemotoxicity (clotting 
time prolongation) were found in 14 cases. 
 Anti snake venom was administered in 23 cases. Minimum and 
maximum dose given were 30ml and 160ml respectively. Reaction to ASV 
was observed in 3 cases. 
 ASV was administered to all 20 cases with haemotoxicity alone, 1 case 
with neurotoxicity alone and 2 cases with a combination of both 
haemotoxicity and neurotoxicity. 
 Of the total of 23 cases to whom ASV was administered all 23 patients 
recovered completely. The 2 patients with respiratory paralysis were on 
 mechanical ventilator support and were extubated after an average period of 4 
days. 
 The remaining 33 cases to whom ASV was not given had no signs and 
symptoms of envenomation. These cases could be the cases of bite by non 
venomous snakes or could be due to bite by a poisonous snake which had just 
had a meal just before the bite (empty salivary glands) or because of timely 
and appropriate first aid measures. 
 
 
 
 
 
 
 
 
 
  
 
 
 
Conclusion  
CONCLUSION 
The gender predominantly inflicted by snake bite in this study is male 
population and most of the snake bite had occurred in outdoor areas 
suggesting that the bite predominantly affects the more active section of the 
population. This is supported by the fact that the age group commonly bitten 
by snakes is between 21 to 30 years.  
 The increased incidence of cases in urban population is probably 
because of the proximity of tertiary institutes where specialized treatment for 
snake bite is available and the increased awareness among urban population 
for the same.  
  The occupational incidence showed that urban victims are 
predominantly constructional workers whereas the suburban area victims are 
predominantly farmers.  
 Seasonal incidence in our study showed that the maximum incidence 
of cases is from may to December which denotes the bite is common in 
monsoon season which leads to flooding of the snake habitats bringing them 
out of their habitats.  
The most common complication seen with snake bite is hemotoxicity 
which was best assessed by clotting time while other complications like 
cellulites, cardiotoxicity and neurotoxicin also occurred.  
Early administration of antisnake venom prevented the complication of 
envenomation inspite of the fact that reaction to antisnake venom occurred 
though rarely.  
Since the difference between venomous and non venomous snakes is 
uncertain bite by any snake should not be ignored and patient bitten by any 
species should be admitted, assessed carefully and treated accordingly. 
 In a tropical country like India, it is imperative to increase awareness 
among the people about the complications of snake bite and educate them 
about the availability of effective specialized treatment. 
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Case Proforma 
 CASE PROFORMA 
 
Name     Age   Sex 
Address    Ward   D.O.A. Time 
        D.O.D  Time 
        IP. No. 
Occupation 
Snake Bite Date   Time 
Treated outside/Native treatment / Not treated 
Snake identified / Not identified 
Indoor bite / Outdoor bite 
SIGNS & SYMPTOMS 
- Pain      Vital Signs Monitored  
- Swelling at Bite site   1. Blood pressure  
- Regional lymphadenopathy  2. Pulse rate 
- Faintness or dizziness   3. Respiratory rate 
- Sweating, Salivation   4. Temperature 
- Nausea, Vomiting   
- Double vision 
- Drooping of eyelid 
- Respiratory difficulty 
- Weakness of limbs 
- Hematuria 
- Hemetemesis, Melena 
- Unconsciousness 
 Site of bite 
Upper extremities  Lower extremities Other parts of body 
1. Finger  1. Toe  
2. Hand 2. Foot  
3. Forearm 3. Leg  
4. Arm 4. Thigh   
Investigations  
Bleeding time Creatine 
phosphokinase 
Alanine transaminase  
Aspartate transaminase  
Clotting time  Lactate 
dehydrogenase 
  
Haemogram B. Culture 
B. urea Non Enteric 
organism  
S-creatinine ECG 
Urine – albumin 
  Sugar 
  Deposits  
  Casts 
  Red blood cells 
B. Sugar X-ray chest   
 
Treatment 
   
1. ASV Dose Reaction  - Immediate  
   - Pyrogenic 
   - Serum Sickness 
(Late) 
2. Blood Transfusion 
3. Peritoneal Dialysis 
4. Hemo dialysis 
5. Fasciotomy for compartmental syndrome 
Outcome 
 ABBREVIATIONS 
 
AB  - Antibiotic 
ACH  - Acetyl Choline  
AH  - Anti Histamine 
ASV  - Anti Snake Venom 
Blood  - Blood Transfusion  
BP  - Blood Pressure  
BT  - Bleeding Time 
CR N  - Cranial Nerve Palsy 
Cr.  - Creatinine 
CT  - Clotting Time  
DIC  - Disseminated Intravascular Coagulation  
E  - Epistaxis  
ECG  - Electrocardiogram 
ELISA - Enzyme Linked Immuno Sorbent Assay  
Exp.  - Expired 
FM  - Fang Mark 
Gum  - Gum Bleeding 
Hb  - Haemoglobin 
HM  - Haematemesis 
HP  - Haemoptysis 
HU  - Haematuria (Microscopic) 
HYD  - Hydrocortisone 
 Limb.  - Limb Muscle Paralysis 
LL  - Lower Limb 
Mech Vent - Mechanical Ventilation  
N  - Native Treatment  
Ne  - Necrosis 
Neo  - Neostigmine 
PD  - Peritoneal Dialysis 
PR  - Pulse Rate  
Resp. Para - Respiratory Paralysis 
RR  - Respiratory Rate  
S  - Swelling 
SB  - Sinus Bradycardia 
SGOT - Serum Glutamate Oxaloacetate Transaminase 
SGPT  - Serum Glutamate Pyruvate Transanimase  
ST-T  - ST-T Changes 
SU  - Suburban 
T  - Trunk 
TC  - Total Count 
U  - Urban  
UL  - Upper Limb 
Ulc  - Ulceration 
V  - Ventilator Support 
PR BP mmHg RR FM S Ne/ Ulc
CR.
N
Resp. 
Para Limb Gum E HP HM HU 0 Hrs 6 Hrs
Hb 
gm% 
TC/ 
cumm
Urea 
mg%
Cr 
mg%
SGOT 
(IU)
SGPT 
(IU)
1 27 M SU 6PM-6AM L.L > 6 N 118 90/70 22 + + - - - - + - - - + 34 12 6.8 9,200 24 1 42 40 ST-T 160 - Blood, HYD -
2 55 M U 12N-6PM L.L 3.5 - 96 130/90 18 - - - - - - - - - - - 4 4 11.5 9,400 26 0.8 48 42 - - - - -
3 54 M U 6PM-6AM L.L <1 - 90 126/80 20 + - - - - - - - - - - 3 3 12.0 8,000 30 0.8 40 40 - - - - -
4 23 M SU 6AM-12N U.L 2.5 - 86 130/90 38 + + + + + - - - - - + 26 9 13.5 9,600 20 0.9 40 38 - 160 - Neo V
5 19 M U 6PM-6AM L.L 3.5 - 84 126/80 18 + - - - - - - - - - - 7 6 13.5 6,400 24 1 42 38 - - - - -
6 27 F U 12N-6PM U.L 1.5 - 78 130/80 18 + - - - - - - - - - - 6 5 10.5 5,400 26 0.9 36 34 - - - - -
7 55 M U 6AM-12N L.L 1.5 - 82 140/90 20 + - - - - - - - - - - 7 5 11.0 5,600 22 0.8 40 32 - - - - -
8 22 M U 12N-6PM L.L 2.5 - 86 120/80 18 + - - - - - - - - - - 6 4 12.5 9,200 28 0.9 43 38 - - - - -
9 38 M SU 6PM-6AM L.L 1.5 - 92 130/90 18 + - - - - - - - - - - 16 6 13.5 9,000 28 1 46 40 - 30 - - -
10 15 M U 6AM-12N L.L 1.5 - 84 110/70 20 - - - - - - - - - - - 4 4 14.0 7,800 22 1.1 30 32 - - - - -
11 50 F U 6PM-6AM L.L 2.5 - 80 130/90 18 + + - - - - - - - - + 18 7 10.5 9,600 24 1.2 40 38 - 100 - - -
12 25 F SU 6PM-6AM L.L 1.5 - 56 120/80 18 + + - - - - - - - - + 21 8 11.5 9,800 30 0.9 44 42 SB 100 R AH, HYD -
13 28 M U 6PM-6AM U.L < 1 - 92 126/84 18 + - - - - - - - - - - 3 3 13.5 6,400 22 0.8 46 44 - - - - -
14 49 F U 6PM-6AM L.L 2.5 - 94 140/90 28 + - - - - - - - - - - 19 8 10.5 9,400 20 0.7 44 42 - 50 - - -
15 21 M SU 6AM-12N L.L 1.5 - 84 110/70 22 + + - - - - - - - - + 16 5 13.0 5,800 24 0.9 30 32 - 50 - - -
16 37 F SU 6PM-6AM L.L 3.5 - 86 130/90 20 + + - - - - - - - - - 18 9 11.0 9,000 26 0.8 32 36 - 50 - - -
17 19 M U 6AM-12N U.L 5.5 N 124 80/60 18 + + + - - - - - - - + 27 12 13.5 9,400 92 3.2 30 34 - 150 - HYD -
18 18 F U 12N-6PM L.L 2.5 - 78 110/70 22 + - - - - - - - - - - 16 8 12.0 9,400 36 0.9 34 36 - 50 - - -
19 33 M U 6AM-12N T 1.5 - 82 130/80 22 - - - - - - - - - - - 5 3 13.0 5,400 28 0.9 30 32 - - - - -
20 35 M SU 6PM-6AM L.L > 6 N 126 130/80 20 + + - - - - + - + - + 23 8 6.5 9,000 30 1 36 34 - 100 - Blood -
21 33 M U 6AM-12N L.L < 1 - 98 120/80 22 + - - - - - - - - - - 6 5 11.5 9,200 24 1 46 44 - - - - -
22 44 M U 6PM-6AM L.L 2.5 - 96 130/90 28 + - - - - - - - - - - 5 4 10.5 9,000 26 0.8 40 42 - - - - -
23 68 M U 12N-6PM L.L 1.5 - 84 140/98 18 - - - - - - - - - - - 4 4 11.5 10,000 22 0.9 38 40 - - - - -
24 22 M U 6PM-6AM L.L 1.5 - 80 128/90 22 + - - - - - - - - - - 5 3 13.5 7,400 20 0.8 36 34 - - - - -
25 22 M SU 6PM-6AM L.L > 6 N 86 140/96 32 + + - + - - - - - - + 38 13 13.5 5,400 156 5.6 40 42 - 150 - Neo, PD -
26 50 M U 6AM-12N U.L 2.5 - 88 136/80 26 + - - - - - - - - - - 2 2 12.0 9,000 30 1.1 32 34 - - - - -
27 40 F U 6PM-6AM L.L 1.5 - 90 146/80 18 + - - - - - - - - - - 17 5 10.5 6,400 32 1.2 34 36 - 50 R AH, HYD -
28 23 M SU 6PM-6AM L.L > 6 - 128 86/70 32 + - - + + - - - - - - 6 6 11.5 9,800 40 1.1 40 42 ST-T 100 - HYD, Neo V
MASTER CHART
S.No. Age Sex
Urban
/ Sub 
urban
Time of 
Bite 
Site of 
Bite
Time 
Lag 
Hrs. 
Native 
Treatm
ent
General Local Neurological Bleeding CT mts. Other 
Treatment
Mech
vent
Lab Investigation 
ECG ASV in ml
Reacti
on
PR BP mmHg RR FM S Ne/ Ulc
CR.
N
Resp. 
Para Limb Gum E HP HM HU 0 Hrs 6 Hrs
Hb 
gm% 
TC/ 
cumm
Urea 
mg%
Cr 
mg%
SGOT 
(IU)
SGPT 
(IU)
MASTER CHART
S.No. Age Sex
Urban
/ Sub 
urban
Time of 
Bite 
Site of 
Bite
Time 
Lag 
Hrs. 
Native 
Treatm
ent
General Local Neurological Bleeding CT mts. Other 
Treatment
Mech
vent
Lab Investigation 
ECG ASV in ml
Reacti
on
29 30 M SU 12N-6PM L.L 2.5 - 94 110/20 22 + - - - - - - - - - - 4 3 13.5 6,000 28 0.8 36 38 - - - - -
30 53 M U 6PM-6AM L.L < 1 - 98 130/80 26 + - - - - - - - - - - 16 5 12.5 9,200 24 0.9 38 40 - 50 - - -
31 30 M U 6PM-6AM L.L 3.5 - 78 120/80 18 + - - - - - - - - - - 5 5 13.5 5,400 22 0.8 40 40 - - - - -
32 31 M SU 6AM-12N L.L 2.5 - 82 130/80 32 + - - - - - - - - - - 17 8 14.0 9,000 22 1 42 42 - 50 - - -
33 39 M U 6PM-6AM U.L > 6 N 86 130/80 20 + - - - - - - - - - - 7 5 13.5 9,400 26 1.1 44 40 - - - - -
34 40 M U 6PM-6AM L.L 1.5 - 78 120/80 22 + + - - - - - - - - - 19 7 13.5 5,400 24 0.9 38 42 - 50 - - -
35 32 M U 6PM-6AM L.L 4.5 - 84 124/80 18 + - - - - - - - - - + 22 7 13.0 9,200 26 1.2 30 34 - 50 - - -
36 33 M SU 6AM-12N U.L 2.5 - 90 136/80 18 + - - - - - - - - - - 6 6 13.0 9,000 28 0.9 28 32 - - - - -
37 19 M U 6PM-6AM L.L 1.5 - 86 128/80 26 + - - - - - - - - - - 8 7 13.5 6,000 30 0.8 34 36 - - - - -
38 45 M U 6PM-6AM U.L < 1 - 88 140/90 18 + + - - - - - - - - - 17 6 12.5 6,200 22 1 30 28 - 50 - - -
39 24 M SU 6AM-12N L.L 2.5 - 80 130/80 26 - - - - - - - - - - - 7 5 13.5 9,000 20 1 32 28 - - - - -
40 26 F U 12N-6PM L.L 1.5 - 70 110/90 22 + - - - - - - - - - - 5 4 11.5 6,100 24 0.8 30 32 - - - - -
41 25 M U 12N-6PM U.L 2.5 - 96 110/70 18 + - - - - - - - - - - 4 4 11.0 8,800 20 0.8 44 42 - - - - -
42 26 M SU 6PM-6AM L.L 1.5 - 40 120/70 20 + - - - - - - - - - - 6 6 12.0 6,800 35 1 42 40 - - - - -
43 40 F U 6PM-6AM L.L 1.5 - 86 130/90 22 + - - - - -  - - - - 7 7 9.5 9,100 26 0.8 40 38 - - - - -
44 26 M U 6AM-12N L.L < 1 hr - 84 126/80 24 - - - - - - - - - - - 6 5 13.0 9,400 28 0.9 38 38 - - - - -
45 17 F SU 12N-6PM L.L 1.5 - 118 90/70 28 + + + - - - - - - - + 31 7 13.0 8,000 26 0.7 40 38 ST-T 100 - HYD -
46 23 M U 6PM-6AM L.L > 6 N 98 120/80 20 + + - - - - - - - - + 23 6 12.5 6,800 27 1 42 40 - 100 R AH, HYD -
47 20 F SU 6PM-6AM U.L 1.5 - 98 110/70 18 + - - - - - - - - - - 6 4 12.0 9,800 24 1 38 42 - - - - -
48 23 M U 6AM-12N L.L 2.5 - 94 110/70 26 + - - - - - - - - - - 4 4 11.5 9,600 26 0.8 36 40 - - - - -
49 34 M U 6PM-6AM L.L < 1 hr - 85 130/90 24 + - - - - - - - - - - 3 3 10.0 8,000 26 0.9 28 32 - - - - -
50 13 F U 6PM-6AM L.L 3.5 - 77 110/70 18 + - - - - - - - - - - 4 4 11.5 10,200 28 0.8 24 26 - - - - -
51 55 M SU 6AM-12N U.L 1.5 - 84 130/90 18 - - - - - - - - - - - 5 4 12.5 9,600 24 0.9 32 32 - - - - -
52 28 F U 12N-6PM L.L 2.5 - 88 100/70 20 + - - - - - - - - - - 6 4 12.5 8,600 28 1 36 38 - - - - -
53 24 M SU 6PM-6AM L.L 1.5 - 90 110/70 22 + - - - - - - - - - - 6 4 13.0 6,700 26 1.1 40 44 - - - - -
54 52 M SU 6PM-6AM L.L 1.5 - 98 130/90 28 + - - - - - - - - - - 18 7 13.0 5,400 24 1 42 40 - 50 - - -
55 50 F U 6AM-12N L.L 3.5 - 84 140/90 22 + + + - - - - - - - + 32 8 12.0 9,400 140 3.6 44 42 - 100 - - -
56 27 M U 12N-6PM U.L 2.5 - 74 110/70 20 + - - - - - - - - - - 5 4 13.5 7,000 28 0.8 44 40 - - - - -
